<DOC>
	<DOCNO>NCT02694744</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety patiromer ( investigational medication ) administer daily ( QD ) give food compare without food treatment hyperkalemia ( high potassium blood ) .</brief_summary>
	<brief_title>Patiromer With Without Food Treatment Hyperkalemia</brief_title>
	<detailed_description>Approximately 110 eligible participant hyperkalemia randomly assign receive patiromer start dose 8.4 g/day , either without food . All participant undergo screen period ( 1 day ) determine eligibility study entry . Eligible participant treat 4 week follow 2 week complete patiromer treatment . There six plan clinic visit Treatment Period two plan visit last dose patiromer Follow-up Period . The dose patiromer may increase decrease ( titrate ) base participant ' individual potassium response .</detailed_description>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>Key Potassium concentration &gt; 5.0 mEq/L two blood draw Screening Stable RAASi medication , take Medications take chronic basis give daily twice daily Informed consent give Key Expected need dialysis Major organ transplant History condition associate pseudohyperkalemia History swallow disorder , gastroparesis , bariatric surgery , bowel obstruction severe gastrointestinal disorder major gastrointestinal surgery Cancer unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Treatment Hyperkalemia</keyword>
	<keyword>Hyperkalemia</keyword>
	<keyword>Potassium</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>